How Much Weight Should You Lose Per Week on GLP-1?
One of the most common questions from GLP-1 patients is "Am I losing weight fast enough?" The answer depends on your medication, dose, starting weight, and how far along you are in treatment. Here is what clinical data and real-world experience tell us about realistic weekly weight loss expectations.
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Individual results vary significantly. Do not adjust your medication dose based on weight loss speed without consulting your provider.
Average Weekly Weight Loss by Medication
| Medication | Months 1-3 | Months 4-8 | Months 9-12+ |
|---|---|---|---|
| Semaglutide | 0.5-1.5 lbs/week | 1-2 lbs/week | 0.5-1 lb/week |
| Tirzepatide | 1-2 lbs/week | 1.5-2.5 lbs/week | 0.5-1.5 lbs/week |
| Retatrutide | 1-2.5 lbs/week | 2-3 lbs/week | 1-2 lbs/week |
These are averages from clinical trial data. Individual results vary based on starting weight, diet, exercise, and metabolic factors.
Factors That Affect Weekly Weight Loss
- Starting weight: Patients with more weight to lose typically lose faster initially
- Dose level: Higher doses produce more weight loss but also more side effects
- Diet quality: High-protein, whole-food diets produce better results than relying on medication alone
- Exercise: Resistance training preserves muscle, which improves body composition even when the scale moves slowly
- Sleep: Poor sleep reduces weight loss by 50% or more in clinical studies
- Stress: Chronic stress elevates cortisol, which promotes fat storage
- Medications: Some medications (antidepressants, steroids, insulin) can slow weight loss
The Pattern of GLP-1 Weight Loss
Phase 1: Rapid Early Loss (Weeks 1-4)
Many patients lose 3-8 pounds in the first month, much of which is water weight from reduced carbohydrate and sodium intake. This initial drop is encouraging but not representative of ongoing fat loss.
Phase 2: Steady Loss (Months 2-8)
This is the productive phase where consistent fat loss occurs. Expect 1-2.5 pounds per week depending on medication and dose. This is when the medication is doing its best work.
Phase 3: Deceleration (Months 9+)
Weight loss slows as your body adapts to its new lower weight. Your metabolism adjusts, and the caloric deficit from reduced eating shrinks because a smaller body needs fewer calories. This is normal, not a failure.
When to Be Concerned
- No weight loss after 8 weeks on therapeutic dose: Discuss with your provider. You may need a dose adjustment or medication switch.
- Losing more than 3 lbs per week consistently: Too-rapid loss increases muscle loss and loose skin risk. See our article on losing too fast.
- Scale fluctuations of 3-5 lbs day to day: This is normal water weight variation. Focus on weekly or biweekly averages, not daily numbers.
Track Your Progress with Trimi
Get started with affordable GLP-1 therapy and track your results. Compounded semaglutide is $99/month and compounded tirzepatide is $125/month. Visit our treatment page to begin.
Frequently Asked Questions
I lost 5 pounds the first week. Will I keep losing that fast?
No. First-week weight loss is mostly water and reduced gut contents. Actual fat loss occurs at 1-2.5 pounds per week. Expect the rate to normalize after the first 2-3 weeks.
I have not lost weight in two weeks. Should I increase my dose?
A two-week stall is normal and does not necessarily indicate a need for dose adjustment. Weight loss is not linear. If the stall persists for 4 or more weeks despite good diet and exercise adherence, discuss dose optimization with your provider.
Does exercise make GLP-1 weight loss faster?
Exercise modestly increases total weight loss but dramatically improves body composition. Patients who exercise preserve more muscle, lose more fat, and look better at the same scale weight. Resistance training is more impactful than cardio for this purpose.
More on Metrics & Tracking
Sources & References
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
- FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).